8-K: Spyre Therapeutics Restates Prior Financials Due to Net Loss Per Share Calculation Error

Spyre Therapeutics has announced a restatement of its previously issued financial statements due to an error in the calculation of net loss per share, specifically related to the treatment of preferred stock.

Summary

• Spyre Therapeutics has determined that its previously issued financial statements for the year ended December 31, 2023, and the interim periods within that year, as well as the quarterly and year-to-date periods ended March 31, 2024, June 30, 2024, and September 30, 2024, should no longer be relied upon.
• This decision was made after identifying a misapplication of U.S. GAAP related to the exclusion of Series A and Series B non-voting convertible preferred stock in the calculation of basic and diluted net loss per share.
• The company also identified a material weakness in internal control over financial reporting solely related to this matter.
• The restatement will correct the net loss per share figures, with significant changes to the reported values.
• For example, the net loss per share for the three months ended June 30, 2023, was originally reported as $(56.79) but will be restated to $(40.14) for common stock, and $(1,605.58) for Series A preferred stock.
• The company intends to file amendments to its Annual Report on Form 10-K and each of the Quarterly Reports on Form 10-Q to reflect these corrections as soon as possible.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the restatement of financials, the identification of a material weakness in internal controls, and the potential for further issues. While the company is taking steps to correct the situation, the overall impact is concerning for investors.

Positives

• The company has identified the error and is taking steps to correct it.
• Management is committed to maintaining a strong internal control environment and believes its remediation efforts will represent an improvement in existing controls.
• The company is working to file the amended reports as soon as possible.

Negatives

• The company's previously issued financial statements should no longer be relied upon.
• There was a material weakness in internal control over financial reporting related to the net loss per share calculation.
• The restated net loss per share figures are significantly different from the originally reported amounts.
• The company may not be successful in promptly remediating the material weakness identified by management.

Risks

• Failure to remediate the material weakness in internal control could result in material misstatements in future financial statements.
• The company may not be able to conclude on an ongoing basis that it has effective internal control over financial reporting.
• Failure to maintain effective internal control could lead to a decline in the stock price and potential delisting from the Nasdaq.
• There is a risk of further delays in filing the amended reports and the discovery of additional information regarding the error.

Future Outlook

The company anticipates filing amendments to its Annual Report on Form 10-K and each of the Quarterly Reports on Form 10-Q to correct the net loss per share figures as soon as possible. Management believes its remediation efforts will improve existing controls.

Management Comments

• Management has concluded that there was a material weakness in internal control over financial reporting solely related to this matter.
• Management is committed to maintaining a strong internal control environment.
• Management anticipates that the new controls, as implemented and when tested for a sufficient period of time, will remediate the material weakness.

Industry Context

Restatements due to accounting errors, particularly in complex areas like earnings per share calculations, are not uncommon in the biotech industry. This event highlights the importance of robust internal controls and adherence to accounting standards.

Comparison to Industry Standards

• Many biotech companies, especially those with complex capital structures involving preferred stock, face challenges in accurately calculating earnings per share.
• Companies like Moderna and BioNTech, while much larger, have also faced scrutiny over their financial reporting practices, though not necessarily related to EPS calculations.
• The restatement highlights the need for Spyre to strengthen its internal controls to meet the standards expected of publicly traded companies, similar to the scrutiny faced by other companies in the sector.

Stakeholder Impact

• Shareholders may experience a negative impact on the stock price due to the restatement and identified material weakness.
• Creditors may reassess their risk exposure to the company.
• Employees may be concerned about the company's financial stability and future prospects.

Next Steps

• The company will file amendments to its Annual Report on Form 10-K and each of the Quarterly Reports on Form 10-Q to correct the net loss per share figures.
• The company will implement and test new controls to remediate the material weakness in internal control over financial reporting.

Key Dates

Keywords

financial restatement, net loss per share, material weakness, internal control, preferred stock, US GAAP, financial reporting, amended filings